Search results
Showing 31 to 45 of 8114 results
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD....
View recommendations for HTE18Show all sections
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (TA969)
NICE is unable to make a recommendation on gefapixant (Lyfnua) for treating refractory or unexplained chronic cough in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA969
We're excited that you're interested in joining a committee and helping us improve health and social care services. By joining, you'll have the...
Technology appraisals are recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.
Our methods and processes (health technology evaluation manual)
Our health technology evaluation manual covers: how we choose medicines and other health technologies to evaluate (topic selection) the steps and...
Costs: charging for technology appraisals and highly specialised technologies
Information about charging for our technology appraisal (TA) and highly specialised technologies (HST) assessments.
The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS. Browse technology...
NICE executive team meeting minutes and agenda
NICE is unable to make a recommendation on melphalan flufenamide (Pepaxti) for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA968
NICE is unable to make a recommendation on pembrolizumab (Keytruda) with gemcitabine and cisplatin for untreated advanced biliary tract cancer in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA966
Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients.
The BNF aims to provide prescribers, pharmacists, and other healthcare professionals with sound up-to-date information about the use of medicines. The
The latest gender pay gap data from NICE
NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social...